SCHEMBL3765698

SCHEMBL3765698

Cc1cccc(-c2csc(N3CCN(C(=O)Nc4cccnc4)CC3)n2)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.64
MAPK1 P28482 5/20 0.64
ALDH1A1 P00352 7/20 0.61
LMNA P02545 6/20 0.61
SMN1; SMN2 Q16637 5/20 0.61
HTT P42858 4/20 0.61
TP53 P04637 2/20 0.61
GAA P10253 2/20 0.61
KMT2A Q03164 3/20 0.58
MEN1 O00255 2/20 0.58
NPSR1 Q6W5P4 1/20 0.58
FAAH O00519 6/20 0.57
HSD17B10 Q99714 1/20 0.54
RECQL P46063 1/20 0.51
ROCK1 Q13464 1/20 0.51
CYP1A2 P05177 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2C19 P33261 1/20 0.49
DNM1L O00429 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3771970 0.89 MAPT (0.63) MAPTMAPK1ALDH1A1LMNASMN1; SMN2
SCHEMBL3761029 0.89 FAAH (0.63) MAPTMAPK1ALDH1A1LMNASMN1; SMN2
SCHEMBL3761168 0.88 FAAH (0.68) MAPTMAPK1ALDH1A1LMNASMN1; SMN2
SCHEMBL3770874 0.88 MAPT (0.83) MAPTMAPK1ALDH1A1LMNASMN1; SMN2
Hydrochloric Acid SCHEMBL3772523 0.88 FAAH (0.67) MAPTMAPK1ALDH1A1LMNASMN1; SMN2
SCHEMBL3766404 0.86 MAPT (0.59) MAPTMAPK1ALDH1A1LMNASMN1; SMN2
SCHEMBL3766412 0.86 MAPT (0.59) MAPTMAPK1ALDH1A1LMNASMN1; SMN2
SCHEMBL3778524 0.84 SMN1; SMN2 (0.61) MAPTMAPK1ALDH1A1LMNASMN1; SMN2
SCHEMBL3770555 0.80 RAB9A (0.61) MAPTMAPK1ALDH1A1LMNASMN1; SMN2
SCHEMBL3765881 0.80 FAAH (0.54) MAPTMAPK1ALDH1A1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080312226-A1 Amide Compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-12-18 US claimed
EP-1813606-A1 AMIDE COMPOUND Takeda Pharmaceutical Company Limited (JP) 2007-08-01 EP claimed
US-7851473-B2 Amide compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-12-14 US disclosed
US-20080312226-A1 Amide Compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-12-18 US disclosed
EP-1813606-A1 AMIDE COMPOUND Takeda Pharmaceutical Company Limited (JP) 2007-08-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312226-A1 Amide Compound FAAH, FAAH2, CNR2 MAPT 3805/4885MAPK1 2636/4885ALDH1A1 353/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.